Floatz logo

PS13

Multiple Sclerosis

National Institute of Mental Health (NIMH)Small moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

182 Active assets in the Multiple Sclerosis cohort.

Asset / SponsorPhaseRating
Fampridine
MGH Institute of Health Professions
Phase 4BBB
Ocrevus
Polpharma Biologics International AG
Phase 4BBB
Nabiximols
Jazz Pharmaceuticals
Phase 4BBB
Teriflunomide
Sanofi
Phase 4BBB
Cladribine
University Hospital, Strasbourg, France
Phase 4BBB

View all 50 →

Same molecule, other indications

PS13 is also rated in:

long COVID-19Dormant
CC
Indicative ·
43 / 100
View asset →
dementiaDormant
CC
Indicative ·
41 / 100
View asset →
amyotrophic lateral sclerosisDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →